Abstract
The efficacy and safety of ceftriaxone in the treatment of bacteremic typhoid fever was studied in 14 patients. Ceftriaxone at a dosage of 50 to 60 mg/kg per day was administered intravenously in two divided doses in 13 patients and as a single dose in 1 patient. When the two patients with medical complications causing persistent fever and the patient who was febrile during therapy were excluded from the calculations, the mean period of defervescence was 4 days. Five to eight days of ceftriaxone therapy was adequate for the patients who were cured. The 14 patients treated with ceftriaxone included 13 patients who were considered cured, although 1 was a convalescent carrier, and one patient who was a treatment failure. There were no relapses in the 11 patients who were monitored for 1 to 8 months. Both peak and trough concentrations of ceftriaxone were well above the ceftriaxone MICs for the Salmonella typhi strains isolated from the patients. We have demonstrated that ceftriaxone can be used successfully in the treatment of typhoid fever in some patients. The advantages of its use include rapid clinical response, short course of treatment, and lack of serious adverse drug reactions.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Bauer A. W., Kirby W. M., Sherris J. C., Turck M. Antibiotic susceptibility testing by a standardized single disk method. Am J Clin Pathol. 1966 Apr;45(4):493–496. [PubMed] [Google Scholar]
- Bittner M. J., Dworzack D. L., Preheim L. C., Tofte R. W., Crossley K. B. Ceftriaxone therapy of serious bacterial infections in adults. Antimicrob Agents Chemother. 1983 Feb;23(2):261–266. doi: 10.1128/aac.23.2.261. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Chau P. Y., Ng W. S., Ling J., Arnold K. In vitro susceptibility of Salmonella to various antimicrobial agents, including a new cephalosporin, Ro 13-9904. Antimicrob Agents Chemother. 1981 Jan;19(1):8–11. doi: 10.1128/aac.19.1.8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Eron L. J., Park C. H., Hixon D. L., Goldenberg R. I., Poretz D. M. Ceftriaxone therapy of bone and soft tissue infections in hospital and outpatient settings. Antimicrob Agents Chemother. 1983 May;23(5):731–737. doi: 10.1128/aac.23.5.731. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Hoffman T. A., Ruiz C. J., Counts G. W., Sachs J. M., Nitzkin J. L. Waterborne typhoid fever in Dade County, Florida. Clinical and therapeutic evaluation of 105 bacteremic patients. Am J Med. 1975 Oct;59(4):481–487. doi: 10.1016/0002-9343(75)90255-7. [DOI] [PubMed] [Google Scholar]
- Klotz S. A., Jorgensen J. H., Buckwold F. J., Craven P. C. Typhoid fever. An epidemic with remarkably few clinical signs and symptoms. Arch Intern Med. 1984 Mar;144(3):533–537. doi: 10.1001/archinte.144.3.533. [DOI] [PubMed] [Google Scholar]
- Samantray S. K., Johnson S. C., Chakrabarti A. K. Enteric fever: an analysis of 500 cases. Practitioner. 1977 Mar;218(1305):400–408. [PubMed] [Google Scholar]
- Uwaydah M., Nassar N. T., Harakeh H., Vartivarian S., Talhouk A., Kantarjian H. Treatment of typhoid fever with cefamandole. Antimicrob Agents Chemother. 1984 Sep;26(3):426–427. doi: 10.1128/aac.26.3.426. [DOI] [PMC free article] [PubMed] [Google Scholar]